1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text revision. Arlington, VA: American Psychiatric Association; 2022.

2. Substance Abuse and Mental Health Services Administration. 2021 NSDUH Annual National Report. Available at https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. Last accessed April 21, 2023.

3. Berrettini W. A brief review of the genetics and pharmacogenetics of opioid use disorders. Dialogues Clin Neurosci. 2017;19(3):229-236.

4. Kendler KS, Prescott CA, Neale MC, Pedersen NL. Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. Arch Gen Psychiatry. 1997;54(2):178-184.

5. Schuckit MA. Vulnerability factors for alcoholism. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. An Unofficial Publication of the College of Neuropharmacology. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.

6. Cadoret RJ, Yates WR, Troughton E, Woodworth G, Stewart MA. Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry. 1995;52(1):42-52.

7. Kendler KS, Ohlsson H, Sundquist K, Sundquist J. The rearing environment and risk for drug abuse: a Swedish national high-risk adopted and not-adopted co-sibling control study. Psychol Med. 2016;46(7):1359-1366.

8. Grant BF, Stinson FS, Harford TC. Age at onset of alcohol use and DSM-IV alcohol abuse and dependence: a 12-year follow-up.J Subst Abuse. 2001;13(4):493-504.

9. Goodwin DW, Schulsinger F, Moller N, Hermansen L, Winokur G, Guze SB. Drinking problems in adopted and nonadopted sons of alcoholics. Arch Gen Psychiatry. 1974;31(2):164-169.

10. Conrod PJ, Pihl RO, Ditto B. Autonomic reactivity and alcohol-induced dampening in men at risk for alcoholism and men at risk for hypertension. Alcohol Clin Exp Res. 1995;19(2):482-489.

11. Centers for Disease Control and Prevention. High-Risk Substance Use Among Youth. Available at https://www.cdc.gov/healthyyouth/substance-use/index.htm. Last accessed April 21, 2023.

12. National Institute of Mental Health. Substance Use and Co-Occurring Mental Disorders. Available at https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health. Last accessed April 21, 2023.

13. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-107.

14. National Institute on Drug Abuse. Screening and Assessment Tools Chart. Available at https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools. Last accessed April 21, 2023.

15. American Society of Addiction Medicine. ASAM Criteria. Available at https://www.asam.org/asam-criteria/about-the-asam-criteria. Last accessed April 21, 2023.

16. Miller WR. Motivational interviewing with problem drinkers. Behavioural Psychotherapy. 1983;11:147-172.

17. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update: Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008.

18. Penberthy JK, Ait-Daoud N, Vaughan M, Fanning T. Review of treatment for cocaine dependence. Curr Drug Abuse Rev. 2010;3(1):49-62.

19. Stitzer ML, Walsh SL. Psychostimulant abuse: the case for combined behavioral and pharmacological treatments. Pharmacol Biochem Behav. 1997;57(3):457-470.

20. Woody GE. Research findings on psychotherapy of addictive disorders. Am J Addict. 2003;12(Suppl 2):S19-S26.

21. National Institute for Health and Care Excellence. Drug Misuse in Over 16s: Psychosocial Interventions. Available at https://www.nice.org.uk/guidance/cg51. Last accessed March 30, 2023.

22. Stoops WW, Lile JA, Rush CR. Monetary alternative reinforcers more effectively decrease intranasal cocaine choice than food alternative reinforcers. Pharmacol Biochem Behav. 2010;95(2):187-191.

23. Barry D, Sullivan B, Petry NM. Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients. Psychol Addict Behav. 2009;23(1):168-174.

24. Peirce JM, Petry NM, Stitzer ML, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006;63(2):201-208.

25. Higgins ST, Heil SH, Dantona R, Donham R, Matthews M, Badger GJ. Effects of varying the monetary value of voucher-based incentives on abstinence achieved during and following treatment among cocaine-dependent outpatients. Addiction. 2007;102(2):271-281.

26. Stitzer ML, Petry NM, Peirce J. Motivational incentives research in the National Drug Abuse Treatment Clinical Trials Network.J Subst Abuse Treat. 2010;38(Suppl 1):S61-S69.

27. Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann NY Acad Sci. 2010;1187:76-100.

28. García-Fernández G, Secades-Villa R, García-Rodríguez O, et al. Long-term benefits of adding incentives to the community reinforcement approach for cocaine dependence. Eur Addict Res. 2011;17(3):139-145.

29. Meyers RJ, Roozen HG, Smith JE. The community reinforcement approach: an update of the evidence. Alcohol Res Health. 2011;33(4):380-388.

30. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol. 1992;47(9):1102-1114.

31. Crits-Christoph P, Gallop R, Temes CM, et al. The alliance in motivational enhancement therapy and counseling as usual for substance use problems. J Consult Clin Psychol. 2009;77(6):1125-1135.

32. Rohsenow DJ, Monti PM, Martin RA, et al. Motivational enhancement and coping skills training for cocaine abusers: effects on substance use outcomes. Addiction. 2004;99(7):862-874.

33. Monti PM, O'Leary TA. Coping and social skills training for alcohol and cocaine dependence. Psychiatr Clin North Am. 1999;22(2): 447-470.

34. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179-187.

35. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70:516-527.

36. Liese BS, Beck AT. Beyond the therapeutic alliance: keeping the drug-dependent individual in treatment. In: Simon Onken L, Blaine JD, Boren JJ (eds). Back to Basics: Fundamental Cognitive Therapy Skills for Keeping Drug-Dependent Individuals in Treatment: NIDA Research Monograph 165. Rockville, MD: National Institute on Drug Abuse; 1997: 207-232.

37. Shawe-Taylor M, Rigby J. Cognitive behaviour therapy: its evolution and basic principles. J R Soc Promot Health. 1999;119(4):244-246.

38. Wright JH, Thase ME, Beck AT. Cognitive therapy. In: Hale RE, Yudofsky SC, Talbott JA (eds). The American Psychiatric Press Textbook of Psychiatry. 4th ed. Arlington, VA: American Psychiatric Publishing; 2008.

39. LexiComp. Available at https://online.lexi.com. Last accessed April 21, 2023.

40. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35(6):537-547.

41. Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism. Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.

42. Miller NS, Gold MS. Alcohol. In: Gold MS (ed). Drugs of Abuse: A Comprehensive Series. New York, NY: Plenum Medical Book Co.; 1991.

43. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1318-1325.

44. Yoshimura A, Kimura M, Nakayama H, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014;38(2):572-578.

45. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.

46. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction. 2004;99(1):21-24.

47. Agency for Healthcare Quality and Research. Pharmacotherapy for Alcohol Dependence: Evidence Report/Technology Assessment No. 3. Available at https://archive.ahrq.gov/clinic/epcsums/alcosumm.htm. Last accessed April 21, 2023.

48. Volpicelli JR, Volpicelli LA, O'Brien CP. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol. 1995;30(6):789-798.

49. Clapp P. Current progress in pharmacologic treatment strategies for alcohol dependence. Expert Rev Coin Pharmacol. 2012;5(4):427-435.

50. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.

51. Pettinati HM, O'Brien CP, Rabinowitz AR, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26(6):610-625.

52. Richardson K, Baillie A, Reid S, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008;103(6):953-959.

53. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(Suppl 20):42-48.

54. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35(2):202-209.

55. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28(10):1517-1523.

56. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence on alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-1922.

57. Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood: a meta-analysis. Addiction. 2018;113(8):1396-1406.

58. Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383-395.

59. Johnson BA, Rosenthal N, Capece JA, et al., for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.

60. Williams SH. Medications for treating alcohol dependence. Am Fam Physician. 2005;72(9):1775-1780.

61. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685.

62. Barrons R, Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther. 2010;35(2):153-167.

63. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86-92.

64. Martinotti G, Di Nicola M, Romanelli R, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol Clin Exp. 2007;22(3):149-156.

65. van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.

66. Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006;30(1):1-5.

67. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105-S120.

68. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66-76.

69. U.S. Food and Drug Administration. FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-higher-dosage-naloxone-nasal-spray-treat-opioid-overdose. Last accessed April 21, 2023.

70. U.S. Food and Drug Administration. FDA Approves Targiniq ER with Abuse-Deterrent Properties. Available at http://wayback.archive-it.org/7993/20170111080314/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm406290.htm. Last accessed April 21, 2023.

71. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3):277-288.

72. Kaye AD, Gevirtz C, Bosscher HA, et al. Ultrarapid opiate detoxification: a review. Can J Anaesth. 2003;50(7):663-671.

73. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Available at https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline. Last accessed April 21, 2023.

74. U.S. Food and Drug Administration. FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults. Last accessed April 21, 2023.

75. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303-2305.

76. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425-1433.

77. Wasan AD, Correll DJ, Kissin I, O'Shea S, Jamison RN. Iatrogenic addiction in patients treated for acute or subacute pain: a systematic review. J Opioid Manag. 2006;2(1):16-22.

78. Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011;71(6):832-843.

79. Ferri M, Minozzi S, Bo A, Amato L. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013;6:CD009879.

80. Bond AJ, Reed KD, Beavan P, Strang J. After the randomized injectable opiate treatment trial: post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug Alcohol Rev. 2012;31(4):492-498.

81. Marlow SP, Stoller JK. Smoking cessation. Respir Care. 2003;48(12):1238-1254; discussion 1254-1256.

82. Pfizer Inc. Chantix (Varenicline) Tablets. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021928s008lbl.pdf. Last accessed April 21, 2023.

83. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.

84. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. 1999;281(1):72-76.

85. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195-1202.

86. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275(16):1247-1251.

87. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.

88. Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults: an official American Thoracic Society (ATS) clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31.

89. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.

90. 90 Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.

91. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(6):588-597.

92. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;22:689.

93. U.S. Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix). Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix. Last accessed April 21, 2023.

94. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000058.

95. Substance Abuse and Mental Health Services Administration. Treating Concurrent Substance Use Among Adults. Available at https://store.samhsa.gov/sites/default/files/pep21-06-02-002.pdf. Last accessed April 21, 2023.

96. National Institute on Drug Abuse. Comorbidity: Substance Use and Other Mental Disorders. Available at https://nida.nih.gov/research-topics/trends-statistics/infographics/comorbidity-substance-use-other-mental-disorders. Last accessed April 21, 2023.

97. National Institute on Drug Abuse. What are the Treatments for Comorbid Substance Use Disorder and Mental Health Conditions? Available at https://nida.nih.gov/publications/research-reports/common-comorbidities-substance-use-disorders/what-are-treatments-comorbid-substance-use-disorder-mental-health-conditions. Last accessed April 21, 2023.

98. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(1):793-802.

99. National Institute on Drug Abuse. Common Physical and Mental Health Comorbidities with Substance Use Disorders. Available at https://nida.nih.gov/publications/research-reports/common-comorbidities-substance-use-disorders/introduction. Last accessed April 21, 2023.

100. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235-243.

101. Morojele NK, Saban A, Seedat S. Clinical presentations and diagnostic issues in dual diagnosis disorders. Curr Opin Psychiatry. 2012;25(3):181-186.

102. Mueser KT, Gingerich S. Treatment of co-occurring psychotic and substance use disorders. Soc Work Public Health. 2013;28(3-4):424-439.

103. Torrens M, Rossi PC, Martinez-Riera R, Martinez-Sanvisens D, Bulbena A. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse. 2012;47(8-9):1005-1014.

104. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18(4 Suppl):S14-S27.

105. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887-1896.

106. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(0):388-406.

107. National Institute on Drug Abuse. Addressing the Stigma that Surrounds Addiction. Available at https://nida.nih.gov/about-nida/noras-blog/2020/04/addressing-stigma-surrounds-addiction. Last accessed April 21, 2023.

108. Aubeg FR, Fairbank JA. Behavioral treatment in posttraumatic stress disorder and co-occurring substance abuse. In: Saigh PA (ed). Posttraumatic Stress Disorder: A Behavioral Approach to Assessment and Treatment. Boston, MA: Allyn and Bacon; 1992: 111-146.

109. Garland EL, Pettus-Davis C, Howard MO. Self-medication among traumatized youth: structural equation modeling of pathways between trauma history, substance misuse, and psychological distress. J Behav Med. 2013;36(2):175-185.

110. Fullilove MT, Fullilove RE, Smith M, et al. Violence, trauma, and post-traumatic stress disorder among women drug users. J Trauma Stress. 1993;6(4):533-543.

111. Wingo AP, Ressler KJ, Bradley B. Resilience characteristics mitigate tendency for harmful alcohol and illicit drug use in adults with a history of childhood abuse: a cross-sectional study of 2024 inner-city men and women. J Psychiatr Res. 2014;51:93-99.

112. Svingen L, Dykstra RE, Simpson JL, et al. Associations between family history of substance use, childhood trauma, and age of first drug use in persons with methamphetamine dependence. J Addict Med. 2016;10(4):269-273.

113. Briere J, Scott CS. Principles of Trauma Therapy: A Guide to Symptoms, Evaluation, and Treatment. 2nd ed. Thousand Oaks, CA: Sage Publications; 2014.

114. Ouimette P, Read JP. Trauma and Substance Abuse: Causes, Consequences, and Treatment of Comorbid Disorders. 2nd ed. Washington, DC: American Psychological Association; 2014.

115. Hien D, Litt LC, Cohen LR, Miele GM, Campbell A. Trauma Services for Women in Substance Abuse Treatment: An Integrated Approach. Washington, DC: American Psychological Association Press; 2009.

116. Yehuda R (ed). Psychobiology of Posttraumatic Stress Disorder: A Decade of Progress. New York, NY: New York Academy of Sciences; 2006.

117. McCauley JL, Killeen T, Gros DF, Brady KT, Back SE. Posttraumatic stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clin Psychol. 2012;19(3):283-304.

118. Miller D, Guidry L. Addictions and Trauma Recovery: Healing the Body, Mind, and Spirit. New York, NY: WW Norton and Company; 2001.

119. Marich J. Eye movement desensitization and reprocessing in addiction continuing care: a phenomenological study of women in early recovery. Psychol Addict Behav. 2010;24(3):498-507.

120. Healthy People 2030. Social Determinants of Health. Available at https://health.gov/healthypeople/objectives-and-data/social-determinants-health. Last accessed April 21, 2023.

121. Substance Abuse and Mental Health Services Administration. Medications for Substance Use Disorders: Statutes, Regulations, and Guidelines. Available at https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines. Last accessed April 21, 2023.

122. Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. Available at https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement. Last accessed April 21, 2023.

123. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press; 2011.

124. Use of Opioids in the Management of Chronic Pain Work Group. VA/DoD Clinical Practice Guideline for the Use of Opioids in the Management of Chronic Pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2022.

125. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR. 2016;65(1):1-49.

126. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

127. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR. 2022;71(3);1-95.

128. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.

129. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181-186.

130. National Comprehensive Cancer Network. Adult Cancer Pain, 2023. Available at https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Last accessed April 21, 2023.

131. Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manage. 2012;17(3):150-158.

132. Federation of State Medical Boards. Guidelines for the Chronic Use of Opioid Analgesics. Washington, DC: The Federation of State Medical Boards; 2017.

133. Centers for Disease Control and Prevention. CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain. Available at https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html. Last accessed April 21, 2023.

134. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/media/79776/download. Last accessed April 21, 2023.

135. American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain and Palliat Care Pharmacother. 2011;25(3):252-264.

136. National Comprehensive Cancer Network. NCCN Guidelines: Treatment by Cancer Type. Available at https://www.nccn.org/guidelines/category_1. Last accessed April 21, 2023.

137. Dalal S, Bruera E. Assessment and management of pain in the terminally ill. Prim Care Clin Office Pract. 2011;38:195-223.

138. Gao W, Gulliford M, Higginson IJ. Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10,202 lung cancer patients. Br J Cancer. 2011;104(11):1704-1710.

139. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29(36):4769-4775.

140. Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. 3rd ed. Baltimore, MD: Johns Hopkins University Press; 2014.

141. New York State Department of Health. Implantable Infusion Pumps for Non-Cancer Pain. Available at https://www.health.ny.gov/health_care/medicaid/redesign/2016/medtronic_sources_dla_rev.htm. Last accessed April 20, 2021.

142. Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009;25(6):1517-1528.

143. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116.

144. Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). Pain Physician. 2017;20(Supp 2):S111-S133.

145. Miner J, Babitz M, Dunn A, Fondario A, Smith M. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2018.

146. Cheattle MD. Risk Assessment: Safe Opioid Prescribing Tools. Available at https://www.practicalpainmanagement.com/resource-centers/opioid-prescribing-monitoring/risk-assessment-safe-opioid-prescribing-tools. Last accessed April 21, 2023.

147. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.

148. Singer JA. Harm Reduction: Shifting from a War on Drugs to a War on Drug-Related Deaths. Available at https://www.cato.org/policy-analysis/harm-reduction-shifting-war-drugs-war-drug-related-deaths. Last accessed April 21, 2023.

149. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S16.

150. American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S Suppl 1):1-91.

151. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127-134.

152. American Chronic Pain Association. ACPA-Stanford Resource Guide to Pain Management: 2021 Edition. Available at https://med.stanford.edu/content/dam/sm/pain/documents/ACPA-Stanford-Resource-Guide-to-Chronic-Pain-Management-2021-Edition-4-18-21-.pdf. Last accessed April 21, 2023.

153. Strickland JM, Huskey A, Brushwood DB. Pharmacist-physician collaboration in pain management practice. J Opioid Manag. 2007;3:295-301.

154. American Society of Anesthesiologists. Opioid Abuse. Available at https://www.asahq.org/madeforthismoment/pain-management/opioid-treatment/opioid-abuse. Last accessed April 21, 2023.

155. Brushwood DB. Screening Controlled Substance Prescriptions for Legitimacy: The VIGIL System. Available at http://www.empaa.org/downloads/EMPAA2010/presentation/BrushwoodDavid_VIGIL_EMPAA2010.pdf. Last accessed April 21, 2023.

156. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26:552-561.

157. Katz NP. Opioid Prescribing Toolkit: A Workbook for Clinicians. New York, NY: Oxford University Press; 2010.

158. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence-based approach. Pain Physician. 2012;15:ES177-ES189.

159. National Institute on Drug Abuse. Benzodiazepines and Opioids. Available at https://nida.nih.gov/research-topics/opioids/benzodiazepines-opioids. Last accessed April 21, 2023.

160. National Institute on Drug Abuse. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at https://nida.nih.gov/sites/default/files/minimizingmisuse_part1.pdf. Last accessed April 21, 2023.

161. American College of Preventive Medicine. Use, Abuse, Misuse and Disposal of Prescription Pain Medication Patient Guide. Available at http://www.yuma.usmc-mccs.org/mccsyuma/assets/File/Drug%20Facts%20Sheets/painmedsclinicalreference.pdf. Last accessed April 25, 2021.

162. U.S. Food and Drug Administration. Disposal of Unused Medicines: What You Should Know. Available at https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know. Last accessed April 21, 2023.

163. Federal Drug Administration. Safe Opioid Disposal: Remove the Risk Outreach Toolkit. Available at https://www.fda.gov/drugs/safe-disposal-medicines/safe-opioid-disposal-remove-risk-outreach-toolkit. Last accessed April 21, 2023.

164. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.

165. Meier B. Increase in Urine Testing Raises Ethical Questions. Available at https://www.nytimes.com/2013/08/02/business/increase-in-urine-testing-raises-ethical-questions.html?_r=0. Last accessed April 21, 2023.

166. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.

167. Holliday S, Hayes C, Dunlop A. Opioid use in chronic non-cancer pain. Part 2: prescribing issues and alternatives. Australian Family Physician. 2013;42:104-111.

168. American Medical Association. Code of Ethics: Opinion 1.1.5 Terminating the Patient-Physician Relationship. Available at https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/code-of-medical-ethics-chapter-1.pdf. Last accessed April 21, 2023.

169. U.S. Department of Health and Human Services Drug Diversion: What Is a Prescriber's Role in Preventing the Diversion of Prescription Drugs? Available at https://www.hhs.gov/guidance/document/drug-diversion-what-prescribers-role-preventing-diversion-prescription-drugs. Last accessed April 21, 2023.

170. Centers for Disease Control and Prevention. Risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.

171. Hannon K. The Prescription Drug Crisis in New York State: A Comprehensive Approach. Available at https://www.scribd.com/doc/82474334/Prescription-Drug-Abuse-Crisis-in-NYS-Comprehensive-Approach-New. Last accessed April 21, 2023.

172. U.S. Drug Enforcement Administration. Drug Scheduling. Available at https://www.dea.gov/drug-scheduling. Last accessed April 21, 2023.

173. U.S. Food and Drug Administration. FDA Approves First Over-the-Counter Naloxone Nasal Spray. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray. Last accessed April 27, 2023.